A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)

Not yet recruiting

• Conditions: Metastatic Pancreatic Cancer

• Registration Number: NCT06688240
• Lead Sponsor: Servier (Tianjin) Pharmaceutical Co. LTD.

Brief Summary

The aim of this phase 4 study is to evaluate the safety profile of ONIVYDE in China mainland.

Primary objective

To characterize the safety of ONIVYDE when used under standard clinical practice in China mainland on the following aspects:

1. Quantify the rate of grade ≥3 neutropenia (primary objective)

2. Serious adverse events and serious adverse drug reactions

3. Adverse events and adverse drug reactions Secondary objective To describe effectiveness in patients receiving ONIVYDE in combination with 5-FU and leucovorin for the treatment of metastatic pancreatic cancer under standard clinical care in China mainland.

(1) Overall survival (2) Overall response (3) Progression free survival (4) Quality of life assessment

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-11
• Study Start: 2024-11
• Study First Submitted: 2024-11-11
• Study First Submitted QC: 2024-11-13
• Last Update Submitted: 2024-11-13
• Study First Posted: 2024-11-14
• Last Update Posted: 2024-11-14
• Primary Completion: 2027-07
• Study Completion: 2027-07

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• The adult patient (≥18 years of age) has given written informed consent to participate in the study.
• The patient has been prescribed for ONIVYDE treatment according to the ONIVYDE China mainland SmPC.
• Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas.
• Documented metastatic disease.
• Patient deemed not eligible or failed previous treatment with gemcitabine or gemcitabine containing therapy.

Exclusion Criteria

• Patients who have experienced a severe hypersensitivity reaction to ONIVYDE or Irinotecan HCL.
• Patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation or confirmed diagnostic of interstitial lung disease.
• Pregnant or nursing (lactating) women.
• Patients without highly effective methods of contraception during study treatment until 3 months after the last dose of the study drug, Specially,7 months for women of childbearing potential and 4 months for male with partners of childbearing potential after the last dose of the study drug.
• Other additional exclusions may be applied by the investigator according to the contexts, in order to ensure that the study population will be non-interventional but representative of all eligible subjects.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To characterize the safety of ONIVYDE when used under standard clinical practice in China mainland on the following aspects:	From enrolment until 30 days after last ONIVYDE administration	(3) Adverse events and adverse drug reactions

Secondary Outcome Measures

Name	Time	Method
To describe effectiveness in patients receiving ONIVYDE in combination with 5-FU and leucovorin for the treatment of metastatic pancreatic cancer under standard clinical care in China mainland.	From FPI to 12 months after LPI	(4) Quality of life assessment(e.g.Karnofsky Performance Status (KPS))